Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Cadisegliatin (TTP399) in Type 1 diabetes, Diabetes. The expected timing is based on the latest available company guidance and may change.
CATT1 (Two Ph3 trials). Collab w/ CinRx Pharma & G42 Investments. 7/29/24- Put on clinical hold. 3/17/25- FDA lifted clinical hold. 8/12/25- Topline data in H2 2026. 11/06/25:- Ph3 CATT1 randomization; reiterated topline data H2 2026. 03/10/26:- Expect CATT1 Ph3 enrollment completion in Q3 2026; runway extends beyond anticipated topline readout. 05/13/26:- CATT1 Ph3 enrollment on track to complete Q3 2026; cash runway through anticipated topline readout. 08/06/26:- CATT1 enrollment Q3 2026; topline H2 2026; Hybrid CATT1 initiation and KOL event before year end 2026.
Verification
Confirm timing and program details against the company announcement or filing.